New study tracks Real-Life impact of secukinumab on HS patients in UAE
NCT ID NCT06785675
First seen Oct 01, 2025 · Last updated May 17, 2026 · Updated 29 times
Summary
This study looks at how satisfied adults with moderate to severe hidradenitis suppurativa (HS) are with their treatment and how their quality of life changes after starting secukinumab. About 48 participants in the United Arab Emirates will fill out questionnaires over a short period. The goal is to understand real-world benefits beyond what is seen in controlled trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Al Ain Abu Dhabi, United Arab Emirates, United Arab Emirates
-
Novartis Investigative Site
Abu Dhabi, United Arab Emirates
-
Novartis Investigative Site
Ras al-Khaimah, United Arab Emirates
-
Novartis Investigative Site
Sharjah city, United Arab Emirates
Conditions
Explore the condition pages connected to this study.